Arnon Nagler, MD, Chaim Sheba Medical Center, Tel Aviv, Israel, discusses advantages and disadvantages to haploidentical transplantation in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Prof. Nagler explains how the safety and efficacy of haploidentical transplantation have improved over the years, and further comments on the important role of post-transplant cyclophosphamide, which has greatly reduced the risk of graft-versus-host disease (GvHD) in patients. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.